Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK Validates High Throughput Format of Gentronix BlueScreen® Assay

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
BlueScreen-384 provides robust, reproducible, and consistent results.

Gentronix has announced the findings of new research published by GlaxoSmithKline (GSK) on the miniaturization and automation of BlueScreen™ HC; a proprietary assay developed by Gentronix for high throughput genotoxicity testing.

Presented in the peer-reviewed Journal of Biomolecular Screening, the study demonstrates that BlueScreen-384 can reduce the need for costly and time-consuming analogue testing in more traditional genotoxicity methods such as the Ames test.

GSK researchers scaled down the assay for use with 384-microwell plates and available reader technologies in high throughput applications and showed that BlueScreen-384 provided robust, reproducible, and consistent results, supporting its use as a routine genotoxicity screening assay.

Importantly, the research also demonstrated how the exploration of structure-activity relationships around a genotoxic lead molecule could be used to identify non-genotoxic analogues.

BlueScreen HC is an innovative assay from Gentronix, which uses genetically modified, human-derived cells containing the GADD45a gene coupled to Gaussia luciferase to detect the genotoxic effects of compounds with high specificity and sensitivity.

Commenting on the publication, Dr Steve Beasley, Commercial Director at Gentronix, said: “The GSK paper provides valuable insights and independent verification for the scalability of our proven BlueScreen HC technology. Additionally, the successful miniaturization of BlueScreen-384 further opens up possibilities for high throughput genotoxicity measurement across a wide range of industries.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.
Thursday, December 20, 2012
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos